Literature DB >> 7852746

Ambulatory pressure decreases on long-term placebo treatment in older patients with isolated systolic hypertension. Syst-Eur Investigators.

J A Staessen1, L Thijs, D Clement, C Davidson, R Fagard, A Lehtonen, G Mancia, P Palatini, E T O'Brien, G Parati.   

Abstract

OBJECTIVE: This long-term study investigated the widely accepted hypothesis that ambulatory pressure does not decrease in patients given placebo.
METHODS: One hundred and twelve older (> or = 60 years) outpatients with isolated systolic hypertension were recruited. Treatment consisted of a placebo during a 3-month baseline period and long-term follow-up.
RESULTS: At baseline, on placebo treatment, clinic systolic/diastolic (SBP/DBP) blood pressure (+/- SD) averaged 176 +/- 12/86 +/- 7 mmHg and 24-h SBP/DBP 151 +/- 15/81 +/- 10 mmHg. These pressures were unaltered in 51 patients in whom the baseline measurements were repeated after a further month on placebo. After the 112 patients had received placebo for 1 year (median), clinic SBP/DBP fell by 6.6 +/- 15.9 (P < 0.001)/1.4 +/- 7.4 (P = 0.06)mmHg and 24-h SBP by 2.4 +/- 10.7 mmHg (P < 0.05), whereas 24-h DBP did not change significantly. The 24-h SBP decreased more with higher baseline level and longer follow-up (5-21 months).
CONCLUSIONS: These findings in older patients with isolated systolic hypertension suggest that in long-term studies the ambulatory pressure may slightly but significantly decrease on a placebo. Like those using conventional sphygmomanometry, long-term studies using non-invasive ambulatory monitoring require a placebo-controlled design.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7852746

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  6 in total

Review 1.  Pulse pressure: an important tool in cardiovascular pharmacology and therapeutics.

Authors:  Roland Asmar; Michel Safar; Patrice Queneau
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study.

Authors:  Focke Ziemssen; Qi Zhu; Swaantje Peters; Salvatore Grisanti; Mohammed El Wardani; Peter Szurman; Karl U Bartz-Schmidt; Tjalf Ziemssen
Journal:  Int Ophthalmol       Date:  2008-04-17       Impact factor: 2.031

3.  Pharmacotherapy for hypertension in adults 60 years or older.

Authors:  Vijaya M Musini; Aaron M Tejani; Ken Bassett; Lorri Puil; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2019-06-05

4.  Blood pressure changes after renal denervation at 10 European expert centers.

Authors:  A Persu; Y Jin; M Azizi; M Baelen; S Völz; A Elvan; F Severino; J Rosa; A Adiyaman; F E Fadl Elmula; A Taylor; A Pechère-Bertschi; G Wuerzner; F Jokhaji; T Kahan; J Renkin; M Monge; P Widimský; L Jacobs; M Burnier; P B Mark; S E Kjeldsen; B Andersson; M Sapoval; J A Staessen
Journal:  J Hum Hypertens       Date:  2013-09-26       Impact factor: 3.012

5.  Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension.

Authors:  Attila Juhasz; Jingtao Wu; Michie Hisada; Tomoka Tsukada; Myung Ho Jeong
Journal:  Clin Hypertens       Date:  2018-02-07

6.  Does the rising placebo response impact antihypertensive clinical trial outcomes? An analysis of data from the Food and Drug Administration 1990-2016.

Authors:  Arif Khan; Kaysee Fahl Mar; Joshua Schilling; Walter A Brown
Journal:  PLoS One       Date:  2018-02-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.